Integer (NYSE:ITGR) Price Target Raised to $163.00

Integer (NYSE:ITGR) had its price target lifted by Truist Financial from $147.00 to $163.00 in a report published on Wednesday,Benzinga reports. Truist Financial currently has a buy rating on the medical equipment provider’s stock.

Several other equities analysts also recently weighed in on ITGR. Bank of America raised their target price on Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Citigroup lifted their target price on shares of Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. Piper Sandler reiterated an “overweight” rating and issued a $140.00 target price (up from $125.00) on shares of Integer in a research report on Friday, October 25th. Benchmark boosted their price target on shares of Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Wells Fargo & Company reiterated an “overweight” rating and issued a $160.00 price objective on shares of Integer in a report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $145.44.

Integer Stock Performance

ITGR opened at $138.65 on Wednesday. The stock has a market cap of $4.65 billion, a P/E ratio of 42.73, a P/E/G ratio of 2.02 and a beta of 1.12. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09. The firm has a fifty day moving average price of $133.58 and a 200 day moving average price of $125.61. Integer has a 1 year low of $94.56 and a 1 year high of $142.76.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.07. The company had revenue of $431.42 million during the quarter, compared to analysts’ expectations of $440.59 million. Integer had a return on equity of 11.63% and a net margin of 6.70%. Integer’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.27 EPS. Equities research analysts anticipate that Integer will post 5.33 earnings per share for the current year.

Institutional Investors Weigh In On Integer

Several large investors have recently bought and sold shares of the stock. Contravisory Investment Management Inc. increased its position in shares of Integer by 55.9% in the 3rd quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 80 shares during the last quarter. Huntington National Bank raised its stake in Integer by 8,933.3% in the third quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 268 shares in the last quarter. Quest Partners LLC lifted its holdings in Integer by 3,688.9% during the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 332 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Integer by 74.1% during the 3rd quarter. GAMMA Investing LLC now owns 653 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 278 shares in the last quarter. Finally, Innealta Capital LLC purchased a new position in shares of Integer in the 2nd quarter valued at about $110,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.